PROF trades 61.3% below Wall Street's consensus target of $12.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes PROF achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 7 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, Profound Medical Corp. (PROF) has a Wall Street consensus price target of $12.00, based on estimates from 7 covering analysts. With the stock currently trading at $7.44, this represents a potential upside of +61.3%. The company has a market capitalization of $225M.
Analyst price targets range from a low of $12.00 to a high of $12.00, representing a 0% spread in expectations. The median target of $12.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, PROF trades at a trailing P/E of -5.2x. Analysts expect EPS to grow +21.0% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
ISRGIntuitive Surgical, Inc. | $151.3B | $427.30 | $597.78 | +39.9% | Buy | 40.9x | 55 |
NVCRNovoCure Limited | $2.0B | $17.72 | $33.00 | +86.2% | Buy | — | 15 |
AEYEAudioEye, Inc. | $93M | $7.41 | — | — | — | — | — |
EDAPEdap Tms S.a. | $178M | $4.75 | $10.00 | +110.3% | Buy | — | 8 |
ARAYAccuray Incorporated | $30M | $0.25 | — | — | — | — | — |
GKOSGlaukos Corporation | $8.8B | $150.65 | $153.33 | +1.8% | Buy | — | 24 |
NNOXNano-X Imaging Ltd. | $86M | $1.24 | $18.00 | +1351.6% | Buy | — | 5 |
PHGKoninklijke Philips N.V. | $26.9B | $28.23 | — | — | Hold | 18.2x | 22 |
GEGE Aerospace | $383.4B | $366.98 | $393.00 | +7.1% | Buy | 48.6x | 34 |
GEHCGE HealthCare Technologies Inc. | $29.5B | $64.89 | $81.00 | +24.8% | Buy | 13.3x | 18 |
Quick answers to the most common questions about buying PROF stock.
The consensus Wall Street price target for PROF is $12, representing 61.3% upside from the current price of $7.44. With 7 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
PROF has a consensus rating of "Buy" based on 7 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $12 implies 61.3% upside from current levels.
PROF's current price is $7.44 with a consensus target of $12 (61.3% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $12 for PROF, while the most conservative target is $12. The consensus of $12 represents the median expectation. These targets typically reflect 12-month expectations.
PROF is moderately covered, with 7 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month PROF stock forecast based on 7 Wall Street analysts shows a consensus price target of $12, with estimates ranging from $12 (bear case) to $12 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on PROF, with a "Buy" consensus rating and $12 price target (61.3% upside). 6 of 7 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
PROF analyst price targets range from $12 to $12, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $12 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.